Alcon recently announced that it has acquired Fluid-Based IOL maker, PowerVision.
US-based PowerVision, Inc. was formed to develop fluid-based accommodating intraocular lenses (IOLs) for cataract surgery patients. The fluid-based IOL utilizes the eye’s natural accommodative response to provide near and intermediate vision, in addition to distance vision commonly provided by basic IOLs.
Dr Rick Wolfe was recently the lead investigator in the first clinical trial here in Australia.
The acquisition demonstrates Alcon’s commitment to driving growth and innovation in advanced technology intraocular lenses (AT-IOLs) to meet the needs of cataract surgery patients who desire spectacle independence.
Dr Rick Wolfe shares this commitment and, as a globally recognised leader in cataract surgery, has played a leading role in introducing and refining techniques in cataract surgery. Dr Wolfe also regularly participates in clinical trials which continue to help shape the future of cataract surgery.
